CINECA IRIS Institutional Research Information System

PELLICANO, Rinaldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.443
EU - Europa 5.168
AS - Asia 3.537
SA - Sud America 545
AF - Africa 205
OC - Oceania 162
Continente sconosciuto - Info sul continente non disponibili 15
Totale 19.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.078
IT - Italia 1.427
CN - Cina 1.304
IE - Irlanda 534
DE - Germania 414
SE - Svezia 404
GB - Regno Unito 388
SG - Singapore 336
TR - Turchia 331
FR - Francia 296
ES - Italia 256
VN - Vietnam 251
PL - Polonia 250
IN - India 242
JP - Giappone 233
ID - Indonesia 230
BR - Brasile 204
UA - Ucraina 182
CA - Canada 168
AT - Austria 161
MX - Messico 150
AU - Australia 143
KR - Corea 130
CO - Colombia 109
RU - Federazione Russa 109
FI - Finlandia 107
NL - Olanda 101
EG - Egitto 92
IR - Iran 92
HK - Hong Kong 77
CL - Cile 76
CH - Svizzera 74
RO - Romania 68
TW - Taiwan 64
BE - Belgio 61
GR - Grecia 59
PT - Portogallo 59
PE - Perù 56
AR - Argentina 52
CZ - Repubblica Ceca 47
HU - Ungheria 40
TH - Thailandia 33
DK - Danimarca 30
IL - Israele 30
PK - Pakistan 30
MY - Malesia 24
SA - Arabia Saudita 24
PH - Filippine 22
ET - Etiopia 21
EC - Ecuador 20
NO - Norvegia 20
KE - Kenya 19
NZ - Nuova Zelanda 18
ZA - Sudafrica 17
PA - Panama 16
EU - Europa 13
IQ - Iraq 13
MA - Marocco 13
VE - Venezuela 13
TN - Tunisia 12
BG - Bulgaria 11
HR - Croazia 11
AE - Emirati Arabi Uniti 10
BD - Bangladesh 9
JO - Giordania 9
LT - Lituania 9
NG - Nigeria 9
RS - Serbia 9
CU - Cuba 8
GT - Guatemala 8
KZ - Kazakistan 7
UY - Uruguay 7
UZ - Uzbekistan 7
CR - Costa Rica 6
DZ - Algeria 6
EE - Estonia 6
SK - Slovacchia (Repubblica Slovacca) 6
BO - Bolivia 5
KW - Kuwait 5
LB - Libano 5
LV - Lettonia 5
BA - Bosnia-Erzegovina 4
PS - Palestinian Territory 4
SI - Slovenia 4
BY - Bielorussia 3
CI - Costa d'Avorio 3
GE - Georgia 3
LU - Lussemburgo 3
MO - Macao, regione amministrativa speciale della Cina 3
SD - Sudan 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
GH - Ghana 2
HN - Honduras 2
IS - Islanda 2
KH - Cambogia 2
NI - Nicaragua 2
NP - Nepal 2
Totale 19.053
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.472
Chandler 947
Fairfield 753
Dublin 523
Ashburn 479
Beijing 466
Houston 399
Torino 389
Redwood City 353
Woodbridge 327
Wilmington 286
Seattle 285
Cambridge 276
Jacksonville 267
Singapore 232
Dong Ket 155
Medford 152
Princeton 151
Nyköping 148
Pisa 143
Vienna 131
Jakarta 130
Villeurbanne 127
Dearborn 125
Warsaw 113
Turin 110
Istanbul 84
Guangzhou 82
Shanghai 82
Rome 73
Milan 72
Nanjing 72
Boston 69
San Diego 63
Hangzhou 57
Fremont 56
London 56
New York 53
Santiago 50
Tokyo 47
Seoul 45
Helsinki 43
Lima 40
Barcelona 39
Chengdu 39
Washington 39
Cairo 38
Wuhan 38
Berlin 37
Bogotá 37
Ankara 36
Taipei 35
Medellín 33
Boardman 32
Ottawa 32
Duncan 31
Santa Clara 31
Upper Marlboro 31
Los Angeles 29
Amsterdam 27
São Paulo 27
Tehran 26
Central District 25
Toronto 25
Zhengzhou 25
Hyderabad 24
Jinan 24
Norwalk 24
Buenos Aires 23
Madrid 23
Moscow 23
Budapest 22
Izmir 22
Bologna 21
Chicago 21
Athens 20
Bangkok 20
Naples 20
Hefei 19
Melbourne 19
Paris 19
Prague 19
Sydney 19
Hebei 18
Pune 18
Silver Spring 17
Addis Ababa 16
Brussels 15
Delhi 15
Fuzhou 15
Montreal 15
San Francisco 15
Surabaya 15
Zapopan 15
Bengaluru 14
Changsha 14
Indore 14
Nanchang 14
Frankfurt am Main 13
Hanoi 13
Totale 11.333
Salva come PNG Salva come JPEG
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.745
Proctitis: a glance beyond inflammatory bowel diseases 1.014
Eosinophilic colitis: clinical review and 2020 update 542
The gut and the Inflammatory Bowel Diseases inside-out: the extra-intestinal manifestations 505
A randomized, double-blind, placebo-controlled pilot study to evaluate the efficacy and tolerability of a novel oral bioadhesive formulation for the treatment of nonerosive reflux disease-related symptoms 435
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets 327
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study 303
Fecal calprotectin: beyond intestinal organic diseases 286
Endocrine manifestations of chronic HCV infection 285
Adalimumab trough levels predict Crohn's disease clinical course 268
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 259
Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients 253
Gut microbiota and chronic exercise in diabetic patients: not only bacteria 244
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy 230
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis 221
Current treatment challenges in the COVID-19 pandemic 211
Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience 210
Physiopathology of intestinal barrier and the role of zonulin 207
Predictors of risk of fracture in inflammatory bowel diseases: a prospective study using FRAX score 207
Helicobacter pylori infection and ischemic heart disease: could experimental data lead to clinical studies? 200
Prevalence of infectious agents in patients with systemic sclerosis: Defining the control group 198
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery: What About Celiac Disease? 179
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index 179
Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message 175
AMOXYCILLIN AND METRONIDAZOLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A 10-YEAR TREND IN TURIN, ITALY 167
Pediatric epilepsy and psychiatric comorbidity: could celiac disease diagnosis improve the outcome? 167
2013 update on celiac disease and eosinophilic esophagitis 163
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 162
Bariatric Surgery and Inflammatory Bowel Disease: a Role for Microbiota? 160
Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? 153
Prevalence ofHelicobacter pyloriinfection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy 149
Comment on "Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp" 147
Does Helicobacter pylori infection increase the risk of adult-onset asthma? 146
Comments on Sulimani et al.: A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females 139
Helicobacter pylori and proton pump inhibitor therapy: One diagnostic method is enough? 139
Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn's disease 139
On Inverse Association between Helicobacter pylori Gastritis and Microscopic Colitis: The European Data 136
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis 136
Efficacy of infliximab biosimilars in patients with Crohn's disease 136
Is Helicobacter pylori the infectious trigger for headache?: A review 134
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 134
Helicobacter pyloriinfection and asthma: Is there a direct or an inverse association? A meta-analysis 133
Response to: Comment on "efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients" 132
Power Doppler sonography to predict the risk of surgical recurrence of Crohn’s disease 129
How ameliorate the adherence in patients with inflammatory bowel disease? 129
Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment 129
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis 128
Inflammation in gastrointestinal disorders: prevalent socioeconomic factors 128
Helicobacter pylori eradication: poor medical compliance from East to West of the world 127
A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms 127
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 126
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA 124
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians 122
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease 122
Modulation of the gut microbiota: opportunities and regulatory aspects 121
P02.38 | Current practice of Gastroenterologists in the treatment of Helicobacter pylori infection in Italy: data from the Italian Registry on H. pylori treatment 119
Features of inflammatory bowel disease followed in a second level center in Northern Italy 119
Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity 116
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 115
Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study" 114
Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction 113
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018 113
Upper GI bleeding in cirrhotic patients: Which method to search for Helicobacter pylori infection? 112
Benefit of supplements in functional dyspepsia after treatment of Helicobacter pylori 112
Osteoporosis, osteopenia, and inflammatory bowel disease: lessons from a real‑world study 111
Helicobacter pylori prevalence: Are the data totally reliable? 109
Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients 109
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 106
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 106
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
COVID-19: a user's guide, status of the art and an original proposal to terminate viral recurrence 105
Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? 102
Endoscopic ultrasound in the preoperative staging of gastric cancer: Key messages for surgeons 97
Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis 97
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study 97
Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy 93
Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results 92
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 92
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 90
Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases 89
P. 11.17: The Role of Adherence to Therapy on the Outcome in Inflammatory Bowel Disease 88
A dive into the stem cells world 87
P. 04.8 ROLE OF BACTERIAL OVERGROWTH IN CROHN'S DISEASE PATIENTS WITH ILEOCOLIC RESECTION: GLUCOSE BREATH TEST EVALUATION 87
The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017 86
A question about dyspeptic patients analyzed using psychometric scores 86
Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis 86
Use of reflux finding score and reflux symptom index for the management of laryngopharyngeal lesions: a pilot study 83
Noncardiac chest pain: a 2018 update 82
Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis 82
The role of hepatic enzymes in Crohn’s disease 81
Infections and stroke: Which potential pathogenic mechanism? 81
Management of inflammatory bowel disease during COVID-19 pandemic 81
Prevalence and prognostic value of hepatic histological alterations in patients with Crohn's disease 80
Inflammation: a highly conserved, Janus-like phenomenon—a gastroenterologist’ perspective 77
Causes of childhood epilepsy: a look for celiac disease? 77
History of Inflammatory Bowel Diseases 75
Irritable bowel syndrome: the clinical approach 74
Practical out-patient management of autoimmune hepatitis 73
Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors 72
CURRENT PRACTICE OF GASTROENTEROLOGISTS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT 72
Totale 17.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.184
article - articoli 0
book - libri 0
conference - conferenze 2.153
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.266 0 0 51 205 104 221 239 318 358 311 203 256
2020/20213.199 190 294 331 254 233 336 224 210 217 274 211 425
2021/20224.313 239 166 179 250 226 233 726 658 510 248 446 432
2022/20234.014 329 299 203 287 369 721 392 300 489 159 264 202
2023/20242.771 256 305 187 247 269 285 163 285 19 212 235 308
2024/2025700 169 252 279 0 0 0 0 0 0 0 0 0
Totale 19.704